Publications by authors named "Victoria G Atkinson"

Claim this Profile
P
Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Oliver John Kennedy, Nina Glassee, Michal Kicinski, Christian U Blank, Georgina V Long, Victoria G Atkinson

Eur J Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Oliver John Kennedy, Michal Kicinski, Sara Valpione, Sara Gandini, Stefan Suciu, Victoria G Atkinson

Eur J Cancer· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
Oliver J Kennedy, Michal Kicinski, Sara Valpione, Sara Gandini, Stefan Suciu, Victoria G Atkinson

Eur J Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.
Adriana Hepner, Victoria G Atkinson, James Larkin, Rebecca A Burrell, Matteo S Carlino

Eur J Cancer· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Alexander M M Eggermont, Christian U Blank, Mario Mandalà, Georgina V Long, Victoria G Atkinson

Lancet Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Andrew Bottomley, Corneel Coens, Justyna Mierzynska, Christian U Blank, Mario Mandalà, Victoria G Atkinson

Lancet Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III).
Victoria G Atkinson, Pietro Quaglino, Massimo Aglietta, Michele Del Vecchio, Roberta Depenni

Cancers (Basel)· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to E. Hindié.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson

J Clin Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson

J Clin Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma.
Robert Mason, Helen C Dearden, Bella Nguyen, Jennifer A Soon, Jessica Louise Smith, Victoria G Atkinson

Pigment Cell Melanoma Res· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoural immunotherapies in oncology.
Wen Xu, Victoria G Atkinson, Alexander M Menzies

Eur J Cancer· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies.
Ines Pires da Silva, Isabella C Glitza, Lauren E Haydu, Romany Johnpulle, Patricia D Banks, Victoria G Atkinson

Pigment Cell Melanoma Res· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Alexander M M Eggermont, Christian U Blank, Mario Mandala, Georgina V Long, Victoria G Atkinson

Eur J Cancer· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature.
Wen Xu, Rebecca J Moor, Euan T Walpole, Victoria G Atkinson

Melanoma Res· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acetylsalicylic Acid Governs the Effect of Sorafenib in -Mutant Cancers.
Heinz Hammerlindl, Dinoop Ravindran Menon, Sabrina Hammerlindl, Abdullah Al Emran, Joachim Torrano, Victoria G Atkinson

Clin Cancer Res· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sentinel node biopsy for melanoma: The medical oncology perspective.
Alexander M Menzies, Victoria G Atkinson, Michael P Brown, Matteo S Carlino, Jonathan Cebon

Aust Fam Physician· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response rate to vemurafenib in patients with B-RAF-positive melanoma brain metastases: a retrospective review.
Marcin R Dzienis, Victoria G Atkinson

Melanoma Res· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis